@ARTICLE{
author={Siefker-Radtke Arlene O|,Lugowska Iwona|,Tupikowski Krzysztof|,Andric Zoran G|0000-0002-1495-2729,Rezazadeh-Kalebasty A |,Curigliano Giuseppe|,Vaena Daniel A|,Vogl FD|,Currie Graeme|,Abella S|,Kelly William Kevin|},
year={2019},
title={Clinical activity of vofatamab (V), an FGFR3 selective antibody in combination with pembrolizumab (P) in metastatic urothelial carcinoma (mUC), updated interim analysis of FIERCE-22},
journal={ANNALS OF ONCOLOGY},
volume={30},
number={},
pages={365-365},
document_type={Meeting Abstract},
} 

@ARTICLE{
author={Siefker-Radtke Arlene O|,Currie Graeme|,Abella Esteban|,Vaena Daniel A|,Kalebasty Arash Rezazadeh|,Curigliano Giuseppe|,Tupikowski Krzysztof|,Andric Zoran G|0000-0002-1495-2729,Lugowska Iwona|,Kelly William Kevin|},
year={2019},
title={FIERCE-22: Clinical activity of vofatamab (V) a FGFR3 selective inhibitor in combination with pembrolizumab (P) in WT metastatic urothelial carcinoma, preliminary analysis.},
journal={JOURNAL OF CLINICAL ONCOLOGY},
volume={37},
number={15},
pages={-},
document_type={Meeting Abstract},
}